Cardiovascular Deal Benchmarks
Heart failure, hypertension, ATTR cardiomyopathy, and PAH deal benchmarks. Benchmarks derived from 76 verified transactions.
76
Total Deals
$336M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
30
license
21
acquisition
13
collaboration
6
option
6
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Sino Biopharmaceutical → AstraZeneca TQC3721 | license | $200M | $1.9B | Jul 2026 |
AirNexis → Haisco dual PDE3/4 inhibitor | license | $40M | — | Jun 2026 |
Jiangsu Hengrui → GSK HRS-9821 | option | $500M | $12.5B | Jun 2026 |
scPharmaceuticals → MannKind scPharmaceuticals subcutaneous cardiology/diuresis products | acquisition | $303M | $303M | Jun 2026 |
Verve Therapeutics → Eli Lilly Verve gene-editing cardiovascular programs | acquisition | $1.0B | $2.3B | May 2026 |
Tenaya Therapeutics Inc. → Alnylam Pharmaceuticals Inc. | collaboration | $10M | $1.1B | Mar 2026 |
35Pharma → GSK HS235 | acquisition | $950M | $950M | Feb 2026 |
Unnatural Products → Novartis | collaboration | $100M | $1.8B | Feb 2026 |
CSL Ltd. → Eli Lilly clazakizumab | license | $100M | — | Feb 2026 |
Argo Biopharmaceutical → Novartis cardiovascular risk reduction | license | $160M | $5.2B | Jul 2025 |
Benchmark Your Cardiovascular Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 76 verified cardiovascular transactions.
Run Cardiovascular Benchmark